Capricor Therapeutics (CAPR) Downgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a sell rating in a research report report published on Tuesday.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

CAPR has been the topic of a number of other research reports. TheStreet lowered Capricor Therapeutics from a c- rating to a d+ rating in a research note on Monday, October 15th. Maxim Group restated a buy rating and set a $4.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, November 14th. HC Wainwright restated a buy rating and set a $9.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday, November 20th. Finally, ValuEngine lowered Capricor Therapeutics from a hold rating to a sell rating in a research note on Friday, December 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $3.00.

Shares of NASDAQ CAPR traded down $0.01 during trading hours on Tuesday, reaching $0.60. 76,236 shares of the stock were exchanged, compared to its average volume of 96,613. The firm has a market cap of $18.10 million, a P/E ratio of -1.36 and a beta of -1.06. Capricor Therapeutics has a 52 week low of $0.31 and a 52 week high of $2.29.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Tuesday, November 13th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.01). The firm had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.90 million. Capricor Therapeutics had a negative return on equity of 159.36% and a net margin of 24.75%. On average, research analysts predict that Capricor Therapeutics will post -0.57 earnings per share for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

See Also: Backdoor Roth IRA Conversion and Strategy

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Rotharium  Reaches Market Capitalization of $4.87 Million
Rotharium Reaches Market Capitalization of $4.87 Million
NewYorkCoin  Market Capitalization Tops $981,527.00
NewYorkCoin Market Capitalization Tops $981,527.00
Brokerages Expect Ardmore Shipping Corp  to Post -$0.26 EPS
Brokerages Expect Ardmore Shipping Corp to Post -$0.26 EPS
Sangamo Therapeutics Inc  Receives $18.80 Average Price Target from Brokerages
Sangamo Therapeutics Inc Receives $18.80 Average Price Target from Brokerages
Reading International  Downgraded by Zacks Investment Research
Reading International Downgraded by Zacks Investment Research
Zacks Investment Research Upgrades Rapid7  to Buy
Zacks Investment Research Upgrades Rapid7 to Buy


Leave a Reply

© 2006-2019 Ticker Report